practice setting, this Guideline has been developed to provide appropriate minimum standards for such services.
1.A | Scope
This MPPG's scope includes medical physics support for the entire treatment process including acceptance testing, commissioning, technical process development, treatment planning and delivery, and quality assurance related to linac-based SRS, SRT, and SBRT, hereafter referred to as SRS-SBRT. For ring-mounted helical tomotherapy linac delivery systems, this document applies to SBRT only. a This MPPG is not intended to address SRS-SBRT procedures based on gamma ray and particle beam (proton or heavier) sources as well as linac-magnetic resonance imaging (MRI) combination machines. 1.C | Definitions 1. End-to-end (E2E) testing -a methodology used to test whether the flow of an application is performing as designed from start to finish. The purpose of carrying out E2E tests in radiation oncology is to identify system dependencies, to ensure that the intended information is correctly passed between various system components, to verify that clinical team members understand their tasks, and to assess overall treatment process accuracy. All aspects of the treatment process should be considered, including immobilization, simulation, respiratory-related motion management, treatment planning, and treatment delivery using a clinically relevant image guidance method. Each step in the E2E testing should be performed by the staff member who will perform the step when the program is clinically implemented.
1.B | Potential limitations and precautions

Medical dosimetrist -a person other than a radiation oncologist
or medical physicist who participates in, performs, and/or assists in the procedures required to develop a radiotherapy treatment plan with related treatment delivery parameters, working under the supervision of a radiation oncologist and qualified medical physicist (QMP).
3. Quality Assurance (QA) -as defined in the AAPM Task Group 100 report: 2 "QA confirms the desired level of quality by demonstrating that the quality goals for a task or parameter are met." In the context of this document, QA refers to the programmatic approach to ensuring quality and safety in SRS-SBRT treatments.
Qualified Medical Physicist (QMP) -as defined by AAPM Pro-
fessional Policy 1. 1 For this practice guideline, the applicable subfield is therapeutic medical physics. Task Group 100 report: 2 "QC encompasses procedures that force the desirable level of quality by evaluating the current status of a treatment parameter, comparing the parameter with the desired value, and acting on the difference to achieve the goal." In the context of this document, QC refers to specific tests performed as described in the QA program. 
Quality Control (QC) -as defined in the AAPM
Stereotactic Radiosurgery (SRS)
-
2.A | Supervision level
This document follows supervision levels defined in AAPM Professional Policy 18. 5 For the delivery of all radiation therapy services, the two responsible professionals are the radiation oncologist and QMP. All other team members work under the supervision of these professionals -clinical procedures supervised by the radiation oncologist and technical procedures supervised by the QMP.
General Supervision:
The procedure is performed under the professional's overall direction and control but the professional's presence is not required during the performance of the procedure. Under General Supervision, the training of the personnel who performs the procedure and the maintenance of personnel competence are the continuing responsibility of the professional.
Direct Supervision: The professional must exercise General
Supervision and be present in the facility and immediately
available to furnish assistance and direction throughout the performance of the procedure.
Personal Supervision: The professional must exercise General
Supervision and be present in the room during the performance of the procedure. 
2.
Perform acceptance testing and commissioning of the SRS-SBRT system, including validation of the treatment planning system accuracy with small fields and tissue heterogeneities (if relevant to the scope of SRS-SBRT services offered), accuracy of targeting through end-to-end (E2E) testing, and quality and precision of the image guidance system.
3. Implement and manage a QA program to ensure proper ongoing performance of the treatment delivery unit, immobilization and simulation devices, image guidance system, and treatment planning system.
4.
Work with other team members to develop standard operating procedures (SOPs) for major steps through the entire treatment process.
5.
Establish a comprehensive safety checklist to act as a guide for the entire treatment process, and determine appropriate methods for the clinic's quality assurance committee to monitor the SRS-SBRT program.
6. Facilitate and manage the clinic's participation in an incident learning system to ensure a transparent, structured evaluation of all "near miss" and actual deviations in the planning and treatment delivery process.
7.
Perform or supervise the dosimetric treatment planning process, providing supervision levels as appropriate to each task (e.g., direct supervision at the initial and final phases of the treatment planning process).
8. Review the final treatment plan for accuracy and deliverability, consulting with the radiation oncologist to ensure that both professionals are confident of the acceptability of the chosen treatment plan. 
2.C.2 | Responsibilities
As stated in the ACR-ASTRO Practice Parameter for SRS 3 and the ACR-ASTRO Practice Parameter for SBRT. 
2.E.2 | Responsibilities
4.
Adequate therapist staffing to ensure that at least two certified radiation therapists are present for every treatment session, with at least one therapist who is appropriately trained in the SRS-SBRT treatment technique being used.
3.B | Instrumentation 1. Redundant radiation detectors suitable for small fields.
2. Reference-grade electrometer suitable for low-signal readings.
3. Appropriate E2E phantoms for the scope of SRS-SBRT services offered, available for use on site in a timely manner (not to exceed 72 hr).
4. QC device to perform a radiation isocentricity beam alignment verification.
3.C | Simulation, planning, and treatment resources 1 . Appropriate devices for patient setup and immobilization.
2. Appropriate devices for proper motion management.
3. Computerized treatment verification system.
Digital access to MRI and positron emission tomography (PET)
image data.
5.
Capability to characterize and quantify internal anatomical changes with respiratory motion (for thoracic and abdominal SBRT services).
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6. Multimodality image fusion capability.
7. Capability to calculate, display, and evaluate composite dose for patients who have received prior radiation therapy.
8.
Linac-based treatment delivery system with appropriate mechanical accuracy, field-aperture size, and resolution for small-target conformality, and image-guidance devices for target localization and verification including motion management technology relevant to the scope of SRS-SBRT services to be offered. 
| ACCEPTANCE TE STING AND COMMISSIONING
4.A | Acceptance testing
The QMP must be involved with the process of facility design, equipment selection and specifications, and provide direct supervision during the acceptance testing process. 9 Customer acceptance test procedures are intended to ensure that the equipment satisfies the performance requirements stated in the purchase agreement, including that the equipment is safe to operate. In some cases, measurements completed as part of the acceptance procedures may also serve as components in establishing the routine quality assurance program. The vendor must demonstrate acceptable system performance.
4.B | Commissioning
To determine the scope of SRS-SBRT commissioning, the QMP must understand the scope of procedures/services to be offered. Commissioning encompasses the overall process of validating the planning and delivery system for the services to be offered, and developing appropriate QC and technical procedures to support these services.
The scope of commissioning must therefore be commensurate with the scope of clinical services to be offered.
4.B.1 | Equipment commissioning
Commissioning of a linac-based treatment delivery system is per- Special consideration: Small-field measurements Small-field dosimetry as used in SRS-SBRT is challenging due to many factors including source size, detector size, and response. 15 As a generalization, even micro-ion-chambers are large relative to the field sizes used in SRS-SBRT due to violation of cavity theory. 16, 17 Generalized approaches to the lack of lateral equilibrium and violation of cavity theory have been addressed in the literature.
18-21
Newer solid-state microdetectors have become available such as diode, plastic scintillators, and synthetic microdiamonds that have shown appropriate characteristics for small-field dosimetry. Evaluations of many commercially available detectors have been published with correction factors for small-field dosimetry. 22 A practical measurement methodology for validating small-field beam data using multiple detectors has also been reported. 23 A newly published code of practice from the International Atomic Energy Agency 24 is also a useful guideline. An important characteristic of any detector used for commissioning is that the detector's active area be of a small size compared to the field size range to be characterized. A daisy-chain method is recommended, using two independent detectors suitable for measuring small fields.
14,22
Upon completion of beam data measurements, key data points (such as percent depth dose at 10 cm depth and output factors for field sizes ≤2.0 cm) should be compared to other machines of identical design, whether in the same institution or from other centers, to guard against gross errors which could arise from inappropriate detector selection or misaligned equipment setup.
Immobilization equipment
Immobilization equipment should be evaluated for its effectiveness in targeting accuracy and precision (e.g., through analysis of shifts after pretreatment imaging for a representative sample of patients for each treatment site), and should be evaluated for its beam attenuation and surface dose characteristics. 12 The effect on surface dose should be clearly articulated to the clinical team prior to implementation of the clinical service.
Treatment planning system
Commissioning of the treatment planning system's dose model should include all aspects described in AAPM Medical Physics Prac- 
Motion management
If the planned scope of clinical services includes treatments affected by respiratory motion, the entire treatment chain (CT simulation, treatment planning, and treatment delivery) should be assessed with E2E testing using a dynamic phantom setup with clinically relevant motion parameters (amplitude, cycle time). The tests should include assessment of spatial targeting accuracy and measurement of delivered target dose.
Independent review
All new SRS-SBRT programs should have independent validation of the beam model and machine calibration prior to initiation of the clinical service. This can be accomplished through E2E phantom tests from the Imaging and Radiation Oncology Core, 25 or through an independent physicist's on-site review.
27
Commissioning report
The scope of commissioning work and key results should be summa- Specific clinical implementation guidance is found in Section VII of the AAPM TG 101 report. 10 These components described in the TG 101 report are also applicable to SRS procedures. The following section is consistent with the TG 101 recommendations, providing additional details deemed relevant to a clinical SRS-SBRT program.
Standard operating procedures
Site-specific SOPs should address the components essential to the patient review, simulation, planning, treatment, and follow-up (see the Appendix for a sample SOP document). Patient safety should be the primary consideration when developing any SOP. c. The SOP should establish certain process expectations for safe implementation such as appropriate time intervals from simulation to treatment with critical points along the path allowing for reconsideration or rescheduling.
d. Every team member has the right and responsibility to halt a case and/or a particular procedure based on safety imperatives.
Patient selection
a. Patient selection criteria should initially be determined using data available from clinical protocols or published guidelines.
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Maximum target size should be documented along with standard prescription dose and fractionation schemes.
b. Where possible, a multidisciplinary review or a peer review of proposed cases should be completed prior to simulation.
If the patient is enrolled in a clinical trial, the rules and guidelines of the clinical trial must be followed. e. In cases of re-irradiation, the cumulative dose should be evaluated by the treating physician. A description of the method used and the outcome of the evaluation should be documented.
f. The use of an isotropic calculation grid size of 2 mm or finer is recommended. The use of a grid size >3 mm is discouraged. 10 For very small targets, a 1 mm calculation grid size may be necessary.
g. Target dose coverage, dose fall-off beyond the target, dose conformity metrics, and compliance with critical structure dose objectives 32 should be clearly reported and signed by the radiation oncologist to confirm that the chosen treatment technique is clinically acceptable.
h. An independent dose calculation check must be performed prior to treatment. 
Ongoing competency
a. The competency checklist should be reviewed periodically (at least annually) and updated as the program evolves. 
End-to-End (E2E) testing
To assess the clinical team's readiness and to validate the SOP, the team should conduct "dry runs" of the entire process, observe and take notes, edit the SOP as needed, and repeat the E2E testing until the process is clear to all participants. The pre-implementation E2E tests and findings should be described in the commissioning report.
Each step in the E2E testing should be performed by the staff member who will perform the step when the program is clinically implemented. E2E process "dry runs" should be performed for each category of SRS-SBRT service, and when a key aspect of the process is changed.
When developing the E2E tests, all aspects of the treatment process should be considered, including immobilization, simulation, respiratory management, treatment planning, and treatment delivery using a clinically relevant image guidance method.
| QUALITY ASSURANCE
5.A | Introduction
A comprehensive QA program for SRS-SBRT is critical to ensure the correct dose is delivered to the target, given the very small target volumes and rapid dose fall-off associated with SRS-SBRT. QA processes and procedures related to SRS-SBRT should be designed to cover the following aspects of the SRS-SBRT program: equipment-specific QA, patientspecific QA, and procedure-specific QA. Safety and QA recommendations have been extensively described in several publications. 3, 4, 10, 33 When equipment performance is found to be out of tolerance, the affected module(s) of the delivery system should be promptly adjusted, and the QMP should verify proper performance before clinical SRS-SBRT services resume. In the event of a significant service interruption, the QMP should coordinate closely with treating physicians to evaluate the impact on patients' treatment schedules given the importance of completing SRS-SBRT treatment courses in a short overall time interval (generally 14 days or less). 35 Patient safety should be the primary consideration in determining when to resume clinical services.
5.B | Minimum equipment-specific QA
The AAPM has published task group reports with recommendations for QA related to SRS-SBRT. TG-142 describes the linear accelerator QA for both conventional radiation therapy procedures and for SRS-SBRT procedures. 36 MPPG 2.a provides recommendations for commissioning and quality assurance of X-ray-based image-guided radiotherapy systems. 29 TG-135 provides specific guidance for QA of robotic radiosurgery systems, 28 and TG-148 provides specific guidance for QA of helical tomotherapy systems. 37 MPPG 5.a provides minimum QA recommendations for treatment planning system dose algorithms. 14 The baseline performance values for routine equipment QA (daily, monthly, and annual QA) should be established during machine commissioning and initial calibration. The SRS-SBRT relevant QA tests, frequencies, and tolerances are summarized in Tables 1-3 for C-arm linac, robotic linac, and ring-mounted helical tomotherapy systems, respectively. In addition, each CT scanner used for treatment planning should be evaluated at least annually to confirm geometric accuracy 13 and constancy of the CT number to density curve.
14 Note: Many tests described in the aforementioned AAPM publications are important for characterizing the system performance regardless of the scope of clinical use; the equipment-specific QA in Tables 1   through 3 
5.D | Procedure-specific QA
Procedure-specific QA addresses issues related to operational tasks, such as checking whether:
1. The workflows to perform SRS-SBRT as defined in the SOP documents are consistently followed.
2.
Staffing level is appropriate.
3. Staff training and continuous training are available and appropriate.
4.
Proper follow-up actions are taken for any actual and/or potential ("near miss") treatment incidents.
As described in the Clinical Implementation section above, each facility should have SOP documents defining the workflow of each SRS-SBRT service. These documents should be reviewed and updated regularly, with at least an annual frequency of review.
T A B L E 1 Minimum SRS-SBRT relevant equipment QA and tolerances for C-arm linac systems.
Frequency Test Tolerance
Daily Laser localization -only if using SRS techniques relying on lasers for target localization (e.g., frame-based SRS without X-ray IGRT) Ongoing competency assessment is necessary given the rapid evolution of technology and treatment methods for SRS-SBRT.
These activities should be properly documented.
5.E | QA program supervision
The QA program should be designed by a QMP who has specific training in SRS-SBRT, and should be reviewed by another QMP with SRS-SBRT experience. The daily QA procedure can be performed by a physicist or radiation therapist and be reviewed by the QMP prior to any SRS-SBRT treatment. Other routine QA or patient-specific QA may be performed by an appropriately trained medical physicist, and reviewed and co-signed by the QMP.
5.F | QA program review
When the SRS-SBRT program is in its initial phase, the QA program should be reviewed bi-annually as the clinical practice and utilization evolves. The frequency can be reduced to annual reviews once the clinical practice and utilization stabilizes. 
| CONCLUSION S
N O T E S
a SRS and SRT using helical tomotherapy were excluded from the scope of this document due to the infrequent use of this technology for SRS and SRT. Exclusion from the scope of this document does not imply any AAPM position regarding the appropriateness of delivering such treatments using helical tomotherapy. b All treatments must occur under supervision of a QMP. In addition, a QMP must provide personal supervision at the first treatment, and as needed for subsequent treatments. The personal supervision should include participation in a time-out checklist, assessment of patient immobilization, assessment of adequate imaging parameters, accuracy of respiratory management (if applicable), consultation on excessive or unusual patient shift requirements during treatment not clearly caused by patient motion on the treatment couch, as well as other patient-or plan-specific needs.
T A B L E 3 Minimum SBRT relevant equipment QA and tolerances for helical tomotherapy systems. Beam quality (each slice width) AE1% PDD 10 or TMR 20 10 Verification of small-field beam data AE2% from baseline for >1.0 cm apertures, AE5% from baseline for ≤1.0 cm apertures CT imaging -treatment -laser coordinate coincidence 1.0 mm E2E localization assessment "hidden target test" 1.0 mm E2E dosimetric evaluation AE5% measured vs. calculated SRS is not included in the scope of this document for helical tomotherapy. Tolerances are absolute accuracy, not variation from baseline, unless otherwise stated.
